新股消息 Frontera Therapeutics递表港交所

Core Viewpoint - Frontera Therapeutics has submitted an application for listing on the Hong Kong Stock Exchange, indicating its intention to raise capital for further development in the gene therapy sector [1] Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative therapies [1] - The company was established in 2019 and has been dedicated to the development of recombinant adeno-associated virus (rAAV) gene therapies [1] - It aims to provide safe, effective, and affordable gene therapy solutions for patients worldwide [1] Product Pipeline - Frontera Therapeutics has developed a differentiated pipeline with clinical advancements, particularly targeting ophthalmic and cardiovascular diseases [1] - The company’s pipeline is positioned to have global best-in-class potential in its therapeutic areas [1] Financial and Market Position - UBS Securities Hong Kong Limited and Haitong International Capital Limited are acting as joint sponsors for the listing application [1]